

Chassieu, 10 may 2021

**ORDINARY AND EXTRAORDINARY GENERAL MEETING TO BE HELD
ON 27 MAY 2021
MODALITIES THROUGH WHICH THE PREPARATORY DOCUMENTS WILL BE MADE
AVAILABLE**

The company's shareholders are invited to attend the ordinary and extraordinary general meeting which will be held on:

Thursday 27 may 2021 – 9 am

at the company registered office - 38 Avenue des Frères Montgolfier- 69680 CHASSIEU

The notice of the meeting, including the agenda and the planned resolutions, was published in the BALO (Bulletin of obligatory legal announcements) of April 21, 2021; the notice convening the meeting was published in the BALO of May 10, 2021.

The documents stipulated by article R.225-83 of the French commercial code are available to shareholders from the moment that the assembly is convened, in line with the applicable regulatory requirements:

- Any registered shareholder can, until the fifth day (inclusive) before the assembly, ask the company to send him these documents. For holders of bearer shares, this right can only be exercised upon presentation of a statement of participation in the accounts of bearer shares held by the authorised intermediary;
- Any shareholder can consult these documents at the company's headquarters during the 15 days preceding the date of the meeting.

For information, electronic voting via the VOTACCESS secure voting platform for the General Meeting of Thursday, May 27, 2021 will be open from May 10, 2021 until Wednesday, May 26, 2021 at 3:00 pm (Paris time). Shareholders wishing to use this platform can consult the access conditions in the notice of meeting and on the company's website (<https://amoeba-nature.com/investisseur/assemblee-generale>).

The results of the votes on resolutions will be posted on the Company's website.

Disclaimer

In the context of the coronavirus epidemic (COVID-19), the procedures for holding the Shareholders' Meeting may change depending on health and/or legal requirements. Shareholders are invited to regularly consult the section dedicated to the Shareholders' Meeting on the Company's website (<http://www.amoeba-nature.com/Investors/General-assembly>).

About AMOÉBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on Euronext Growth. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba

Valérie FILIATRE

Directeur Général Adjoint

+33 4 26 69 16 00

v.filiatre@amoeba-nature.com

Calyptus

Relations investisseurs & Presse

Grégory BOSSON / Mathieu CALLEUX

+33 1 53 65 37 90 /91

amoeba@calyptus.net